Norm O'Rourke1, Andrew Sixsmith2, Tal Michael3, Yaacov G Bachner4. 1. Department of Public Health and Multidisciplinary Center for Research On Aging, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Be'er Sheva, Israel. ORourke@bgu.ac.il. 2. STAR Institute, Simon Fraser University, Vancouver, BC, Canada. 3. School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. 4. Department of Public Health and Multidisciplinary Center for Research On Aging, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Be'er Sheva, Israel.
Abstract
BACKGROUND: Research with the BDSx (Bipolar Disorder Symptom Scale) suggests a 4-factor structure of responses: two depression (cognitive, somatic) and two hypo/mania factors (elation/loss of insight, affrontive symptoms). The two depression and two hypo/mania factors are correlated; and affrontive symptoms of hypo/mania (e.g., furious, disgusted, argumentative) are positively correlated with both depression factors suggesting pathways for mixed symptom presentation. This grouping of affrontive symptoms of hypo/mania organically emerged in exploratory research and has subsequently been supported in confirmatory analyses between samples and over time. The BDSx has been clinically validated with BD outpatients. RESULTS: Over 19 days, we recruited an international sample of 784 adults with BD using micro-targeted, social media advertising (M = 44.48 years, range 18-82). All participants indicated that they had BD (subtype, if known) and had been diagnosed with BD (month, year). This sample size was sufficient to confirm the 4-factor model across subtypes and compare the three (BD I, BD II, BD NOS). Responses to 19 of 20 BDSx items were psychometrically consistent across BD subtypes. Only responses to the 'hopeless' item were significantly higher for those with BD II. CONCLUSIONS: When comparing models, it appears that affrontive symptoms are significantly and uniformly associated with hypo/mania and both depression factors across subtypes. In contrast to BD diagnostic criteria, this suggests that affrontive symptoms are central to the clinical presentation of hypo/mania and mixed symptomology across BD subtypes.
BACKGROUND: Research with the BDSx (Bipolar Disorder Symptom Scale) suggests a 4-factor structure of responses: two depression (cognitive, somatic) and two hypo/mania factors (elation/loss of insight, affrontive symptoms). The two depression and two hypo/mania factors are correlated; and affrontive symptoms of hypo/mania (e.g., furious, disgusted, argumentative) are positively correlated with both depression factors suggesting pathways for mixed symptom presentation. This grouping of affrontive symptoms of hypo/mania organically emerged in exploratory research and has subsequently been supported in confirmatory analyses between samples and over time. The BDSx has been clinically validated with BD outpatients. RESULTS: Over 19 days, we recruited an international sample of 784 adults with BD using micro-targeted, social media advertising (M = 44.48 years, range 18-82). All participants indicated that they had BD (subtype, if known) and had been diagnosed with BD (month, year). This sample size was sufficient to confirm the 4-factor model across subtypes and compare the three (BD I, BD II, BD NOS). Responses to 19 of 20 BDSx items were psychometrically consistent across BD subtypes. Only responses to the 'hopeless' item were significantly higher for those with BD II. CONCLUSIONS: When comparing models, it appears that affrontive symptoms are significantly and uniformly associated with hypo/mania and both depression factors across subtypes. In contrast to BD diagnostic criteria, this suggests that affrontive symptoms are central to the clinical presentation of hypo/mania and mixed symptomology across BD subtypes.
Authors: Norm O'Rourke; Marnin J Heisel; Sarah L Canham; Andrew Sixsmith; Hamed Yaghoubi-Shahir; David B King Journal: Aging Ment Health Date: 2017-04-24 Impact factor: 3.658
Authors: Ludovic Samalin; Ingrid de Chazeron; Eduard Vieta; Frank Bellivier; Pierre-Michel Llorca Journal: Bipolar Disord Date: 2016-03-06 Impact factor: 6.744